Background: The surgical resection of colorectal cancer with liver metastases (CLM) has proven to be the most important modality for long-term survival, while effective biomarkers for outcome prediction or postoperative surveillance are still lacking. Currently, circulating biomarkers obtained from a liquid biopsy are widely used to assess the treatment response, disease recurrence and progression. In this study, we analyzed the value of the liquid biopsy, which includes circulating tumor DNA (ctDNA) and cell-free DNA (cfDNA), in patients with CLM. Methods: Capture-based targeted deep sequencing was performed on matched pre-surgery, post-surgery and liver metastatic tissues of 20 CRC patients who underwent the resection of liver metastases between May and September 2017 using a panel consisting of 41 genes. Mutation landscapes obtained from pre-surgery plasma samples and metastatic tissue samples were compared. Results: Collectively, we identified 47 mutations from 17 pre-surgery plasma samples (85%), and the remaining 3 patients had no mutation detected from the panel. We revealed a high by-variant concordance rate of 82.14% between pre-surgery plasma samples and liver metastatic tissue samples. We further analyzed the correlation between ctDNA, cfDNA, CEA and tumor burden and revealed a positive correlation between ctDNA and tumor burden (R=0.69, p=0.002). As of the date for data cutoff, 8/20 patients experienced relapse. Our study also demonstrated that pre-surgery ctDNA (p<0.001), cfDNA (p=0.001) and CEA (p=0.012) levels had predictive value for relapse. Patients with low pre-surgery ctDNA (p<0.001), cfDNA (p=0.001) or CEA (p=0.012) levels were more likely to experience prolonged progression-free survival. Conclusion: Our data demonstrate that the genomic profile obtained from ctDNA is comparable with the genomic profile obtained from metastatic liver tumors. Furthermore, our study also show that pre-surgery ctDNA levels are positively correlated with tumor burden. In addition, presurgery ctDNA, cfDNA and CEA levels have predictive value for relapse.
Introduction
Colorectal cancer (CRC) is currently the third most common cancer worldwide. Approximately 25% of patients with CRC have liver metastases at the initial diagnosis, and another 20-30% of patients will eventually develop liver metastases, contributing to the high mortality rates reported for CRC.
1,2 CRC patients with liver metastases (CLM) are thought to have aggressive clinicopathological features, unfavorable cancer biology and poor survival outcomes. 3 Although surgical resection of the primary tumor and liver metastases has proven to offer long-term survival, the optimal timing and sequence of chemotherapy and surgery are still undetermined. 4 In clinical practice, the involvement of a multidisciplinary team (MDT) in the management of CLM is recommended in clinical guidelines by integrating molecular, clinical and pathological features to customize therapy. 5 Due to the advancement of high-throughput sequencing technology, the elucidation of genetic features is more feasible, and a molecular classification with distinct biological behaviors for CRC was proposed by the international consensus. 6, 7 Although tissue biopsy or surgical resection samples are still regarded as the gold standard for mutation profiling, liquid biopsy is widely used in clinical settings. Obtaining tissue biopsies is not only invasive but also biased because of its temporal and spatial snapshot nature. Furthermore, samples obtained from patients who have progressed on previous treatment options might not be adequate for NGS testing. [8] [9] [10] Hence, the application of the liquid biopsy, which includes circulating tumor cell (CTC), circulating cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA), has been gaining momentum in clinical practice. cfDNA includes DNA fragments in cell-free components that are released into the bloodstream by cells. The small proportion of cfDNA from neoplastic cells is referred to as ctDNA. Previous studies have reported the value of ctDNA in colorectal cancer management. Several studies confirmed the predictive value of ctDNA in therapeutic response in metastatic colorectal cancer, and prognostic significance of postoperative ctDNA in early stage colon cancer and locally advanced colon and rectal cancer. [11] [12] [13] [14] [15] ctDNA has also showed potential clinical utility to guide therapeutic decisionmaking in colorectal cancers. 13, 14 Considering that the surgical resection of liver metastases is the major choice for CLM treatment, major efforts are needed to elucidate the clinical value of ctDNA in CLM with regard to surgical benefits and optimal treatment strategies. [15] [16] [17] In the current study,
we prospectively analyzed the application of perioperative ctDNA in predicting tumor burden and the risk of recurrence in patients with CLM undergoing the resection of liver metastases. , where r is the maximum tumor radius) and is referred to as the total tumor volume (TTV). 18 All patients were followed-up every 3 to 6 months after the surgery. The last follow-up date was November 27, 2018. This study was reviewed and approved by the Institutional Review Board ofFUSCC. Written informed consent was obtained from all patients to use their cancer tissue and clinical and outcome information for future academic studies during their first hospital admission. This study was carried out in accordance with the Declaration of Helsinki.
Materials and Methods

Study Design
Tissue DNA Extraction DNA of metastatic tumor tissue was extracted using a QIAamp DNA FFPE tissue kit (Qiagen, California, USA) according to the manufacturer's instructions. DNA concentration was measured with a Qubit dsDNA assay (Life Technologies, California, USA).
DNA Extraction from Blood and cfDNA Extraction
Serial blood samples were collected at two defined time points: pre-surgery (within 7 days before surgery) and post-surgery (within 7 days after surgery). 10 mL of blood were collected in the streck tubes (DNA preserving tubes) and send to be processed immediately within 72 h of collection. Whole blood was centrifuged at 2400×g for 10 min at 4°C. After discarding the red blood cells and buffy coat, we centrifuged the plasma at 16,000×g for another 5 min at 4°C. Supernatants were subsequently stored at −80°C until further analysis. cfDNA from plasma was purified using a QIAamp Circulating Nucleic Acid kit according to the manufacturer's instructions.
Next-Generation Sequencing (NGS) Library Preparation
Tissue DNA was sheared using a Covaris M220 ultrasonicator. The sheared tissue DNA and purified cfDNA underwent end repair, phosphorylation and adaptor ligation. Fragments of 200-400 base pairs (bp) were selected using Agencourt AMPure beads (Beckman Coulter, Brea, CA, USA) followed by hybridization with capture probe baits, hybrid selection with magnetic beads and polymerase chain reaction (PCR) amplification. A bioanalyzer high-sensitivity DNA assay was performed to assess the quality and size of the fragments. A minimum of 50 ng of DNA was used for library construction. Twelve PCR cycles were used for library amplification. The indexed samples were sequenced on a NovaSeq system (Illumina, Inc., San Diego, CA, USA) with paired-end reads with read lengths of 150 bp.
Capture-Based Targeted DNA Sequencing
The genomic profiles of tissue and cfDNA samples were assessed by performing capture-based targeted deep sequencing using the ColonCore panel (Burning Rock Biotech, Ltd.), which covers the whole exons of 41 colon cancer-related genes (Supplemental Table 1 ) and spans 213 kb of the human genome. DNA quality and size were assessed by a high sensitivity DNA assay using a bioanalyzer. All indexed samples were sequenced on a NextSeq 500 system (Illumina, Inc.) with pair-end reads.
Sequencing Analysis
Sequencing data in FASTQ format were mapped to the human genome (hg19) using BWA 0.7.10. Local alignment optimization, variant calling, and annotation were performed using GATK 3.2, MuTect, and VarScan, respectively. DNA translocation analysis was performed using both TopHat2 and Factera 1.4.3. Gene-level copy number variation was statistically assessed after normalizing the read depth at each region by the total read number and region size and correcting for GC bias using the LOESS algorithm. The amount of ctDNA was calculated as the product of the maximum allelic fraction (MAF) and the cfDNA amount.
Statistics
Normality was assessed with the Shapiro-Wilk test. Continuous variables, such as CEA, cfDNA, and ctDNA, were compared using the Wilcoxon signed-rank test. Correlations between tumor burden and the circulating biomarkers (CEA, cfDNA, and ctDNA) were assessed using Pearson's correlation after the log base 10 transformation of both variables. The Kaplan-Meier test was used for the survival analysis. The Log rank test was performed to determine statistical significance. Progression-free survival (PFS) was measured from the date of baseline blood collection to the date of progression of liver metastases after surgical resection. The concordance between mutations obtained from tissue and plasma samples was calculated as the ratio of the number of mutations detected in both plasma and tissue samples. All analyses were set at a two-sided p value <0.05 as the threshold for statistical significance. Data are expressed as the mean ± standard deviation (SD). All the analyses and data visualization were performed with RStudio-1.0.143.
Results
Patient Characteristics
Collectively, 20 CRC patients with liver metastases who underwent surgical resection of their liver metastases at the Department of Colorectal Surgery, FUSCC between May 2017 and September 2017 were enrolled. The mean age was 55±13 years. The cohort consisted of 6 females and 14 males. The mean pre-surgery serum CEA level was 31.89 ±47.08 ng/mL; 7 patients fell within the normal range (≤5ng/mL), and 13 patients had elevated levels (>5ng/mL). The primary CRC tumor sites included 9 on the rectum, 6 on the left-sided colon and 5 on the right-sided colon. Nine patients received simultaneous resection, and the remaining 11 patients received two-stage resection for colorectal cancer and liver metastases. For patients who received two-stage resection, they had surgery on their primary site first. Eleven patients received fluorouracil-based neoadjuvant therapy with median time of 3 regimens and 16 patients received fluorouracil-based adjuvant chemotherapy with median time of 5 regimens. Detailed patient characteristics are shown in Table 1 .
Mutation Landscape in ctDNA of CLM Patients
Collectively, we identified 56 mutations spanning 17 genes from the liver metastasis tissue samples of 19 patients, as shown in Figure 1 . One patient had no mutation identified from this panel. Their corresponding white blood cells were also sequenced to be used as references to filter out germline mutations. The on-target ratio was 72.5%, with a unique depth of 886x. The most commonly mutated gene was TP53, occurring in 70% (15/20) of patients, followed by APC and KRAS, occurring in 55% (11/20) and 45% (9/ 20) of patients, respectively. Furthermore, we identified 47 mutations spanning 14 genes from the pre-surgery blood samples, which had a mean cfDNA amount of 17.16 ±15.76 ng/mL and a mean ctDNA amount of 1.46±3.70 ng/mL, which was calculated by multiplying the cfDNA amount by the maximum allelic fraction (MaxAF). At least one mutation was detected in 17 (85%) patients, and the pre-surgery plasma samples of 3 patients had no mutation detected from this panel. Similar to the liver metastasis tissue samples, the most commonly mutated gene was TP53, occurring in 60% of patients (12/20), followed by KRAS and APC, both occurring in 50% (10/ 20) of patients. Collectively, tissue and pre-surgical plasma samples achieved a by-variant concordance of 82.14% (46/ 56) and a by-patient concordance of 70% (14/20) . Twentyfour mutations were identified only in the tissue samples, and 1 mutation was identified only in plasma samples. Overall, we identified 10 mutations from the 4 postsurgical plasma samples. All other patients had no mutation detected in their post-surgical samples. For plasma samples, the on-target ratio was 72.2%, with a unique depth of 7803x. The mean cfDNA amount was 48.89 ±29.18 ng/mL. The mean ctDNA amount was 0.87 ±3.31 ng/mL. It is interesting to note that the cfDNA amount was significantly increased (p<0.01) after surgery, but the ctDNA level was significantly reduced (p<0.01) (Figure 2 ).
Prognostic Value of ctDNA for CLM
We further investigated the impact of the sequence of liver resection on ctDNA. As shown in Table 2 , for patients who received two-stage resection, 91% (10/11) had detectable ctDNA prior to resection of the liver tumor; in contrast, only 9% (1/11) of patients had detectable ctDNA after surgery. For patients who received simultaneous resection, 77% (7/9) of patients and 33% (3/9) of patients had detectable ctDNA prior to and after liver resection, respectively.
Next, we investigated the association between the tumor volume of liver metastases and CEA, cfDNA and ctDNA. The tumor volume was 326.00 ± 302.19 mL. We determined that only the ctDNA levels were strongly correlated with tumor burden (p=0.002, Figure 3) . Furthermore, we also investigated the correlation between PFSand the 3 abovementioned biomarkers (ctDNA, cfDNA and CEA). At the time of analysis (December 15, 2018), the PFS of 19 patients was evaluable; one patient was lost to follow-up. None of the 19 patients were deceased. Eight (42%) of the 19 patients experienced relapse of liver metastases. Our data showed that patients with a normal pre-surgical CEA level experienced longer PFS than patients with an elevated pre-surgical CEA level (p=0.009). Furthermore, dichotomous analyses revealed that patients with low presurgical cfDNA (p=0.009) and ctDNA (p<0.001) levels experienced longer PFS (Figure 4 ). We also evaluated the impact of post-surgical ctDNA on PFS. Only 4 patients had detectable ctDNA after surgery. Although this study did not reveal any difference in PFS between patients with and without post-surgical ctDNA, larger studies are needed to further investigate this finding. Collectively, our results reveal that pre-surgical ctDNA, cfDNA and CEA levels are associated with PFS.
Discussion
Hepatic metastasis, often observed in patients with advanced CRC, is a significant clinical problem. For patients with isolated liver metastasis, numerous regional treatments are available, among which surgery remains the gold standard. However, diverse responses in progression-free survival have been observed. CEA is believed to be associated with PFS. The current was a feasibility study aimed at determining the association of CEA, ctDNA and cfDNA with PFS in this patient population. Both ctDNA and cfDNA levels have been suggested to impact the PFS of patients with various cancer types undergoing diverse treatments. 19 In the current study,
we also compared and contrasted the genomic profiles of presurgical and post-surgical plasma samples as well as tissue samples of liver metastases. Previous studies have reported the concordance of genetic profiles between ctDNA and metastatic tissue. Bachet et al 20 demonstrated excellent concordance between RAS status in plasma and tumor tissue from patients with colorectal cancer and liver metastases in a cohort of 412 patients with the κ coefficient of 0.71 (95% CI, 0.64-0.77) and accuracy of 85.2% (95% CI, 81.4% to 88.5%). Consistent with these results, our data indicated high consistency between pre-surgery ctDNA and liver metastasis tissue, achieving 82% by-variant concordance. The observed heterogeneity is due to the nature of a tissue biopsy, which is a snapshot of the tumor. We observed a significant decrease in ctDNA after surgery due to tumor ablation. More interestingly, we observed that patients who underwent simultaneous resection were more likely to have detectable ctDNA after surgery than patients who received two-stage resection (33% vs 9%). What contributes to this difference warrants further investigation.
Previous studies have demonstrated the correlation of ctDNA and tumor burden. The assessment of tumor burden is always critical in the management of metastatic cancer, which might help guide the selection of therapeutic regimens. Radiographical imaging, including computed tomography (CT), magnetic resonance imaging (MRI), and positron-emission tomography coupled with CT (PET-CT), are commonly used to assess tumor burden. However, the sensitivity is limited, especially when the patient is undergoing chemotherapy. Bhangu et al 21 indicated that circulating cell-free methylated tumor DNA was correlated with tumor burden, as measured by the CT volume in CLM, and predicted an early response in patients receiving systemic chemotherapy. In the current study, we evaluated the correlation between tumor volume and the total volume of surgically resected and radiofrequency-ablated tumor tissue as the reference to accurately measure tumor burden. Moreover, we studied the association between tumor burden and three tumor markers: CEA, cfDNA, and ctDNA. Our study revealed that elevated CEA and high levels of cfDNA and ctDNA were associated with short PFS. However, only ctDNA was significantly associated with the tumor burden of CLM. We observed a significant increase in the mean cfDNA, from 17.16 ng/mL to 48.89 ng/mL after surgery, potentially due to the relatively short interval between surgery and sampling (within 7 days after surgery) leading to a release of inflammatory factors and necrosis debris of cells under stress. 22, 23 In contrast, the ctDNA level released from tumor cells was reduced significantly, from 1.47 ng/mL to 0.87 ng/mL, due to ablation and relatively limited chance of finding ctDNA in a large amount of cfDNA. Our finding was consistent with those from previous studies on CRC after primary tumor resection, which indicated that ctDNA was more sensitive than cfDNA in monitoring disease load. 24 A recent study in metastatic colorectal cancer demonstrated similar findings, indicating that ctDNA was likely to be more correlated with tumor metastasis and tumor markers than cfDNA. 25 Collectively, our results suggest that ctDNA can reflect tumor burden. This study also had some limitations. First, this prospective study had a limited number of patients. Larger multicenter studies are needed to further validate our findings. The panel used included only 41 genes, which may underestimate the percentage of patients with mutations. Patients with no mutation detected from this panel were regarded as having no ctDNA. Risk adjustment based on known factors that impact progression-free survival was not performed. Due to the relatively short follow-up time, overall survival data were not mature enough to use at the time of data cutoff. Therefore, the prognostic value of ctDNA, cfDNA and CEA could not be evaluated. We are still following all patients for OS. No standard protocol was used to monitor recurrence. Most patients were monitored every 3 months. In conclusion, our data indicate that the mutations obtained from ctDNA are highly consistent with those obtained from resected liver metastases and are associated with tumor burden and PFS, which may be better than serum CEA and cfDNA.
